L
LIOM
The ultimate health wearable, live consciously
About LIOM
Liom, formerly known as Spiden, is a company focused on non-invasive biomarker monitoring. The company is developing a wearable device that uses a proprietary light and AI deep-tech platform for real-time, needle-free glucose monitoring. This technology also has the potential to measure other biomarkers, such as hydration and alcohol levels, and track vital signs.
The company's business model appears to be centered around the development and sale of this wearable device. The target market includes individuals who need to monitor their glucose levels regularly, such as people with diabetes, as well as a broader consumer base interested in health and wellness monitoring. By offering a calibration-free and non-invasive solution, Liom aims to provide a more convenient and pain-free alternative to traditional glucose monitoring methods.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Freienbach, Switzerland
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 61.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Weight Management, Remote Monitoring, Metabolism, Tech for Biotech and Pharma, Tech for Hospitals and Clinics, Drug Delivery Systems, Digital Care, remote health monitoring, DT and LS, science-based
- Technology
- IoT InternetOfThings
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | $16M | $125M | Melih Odemis · Alejo Costa Ribalta · Red Bull Ventures · Marc Maurer | ↗ |
| SERIES AOther financing | Dec 2024 | $25M | $100M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for LIOM is 4.2K monthly website visits, down 2.3% over the last three months. LIOM's team declined 2.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Daniel Gutenberg
Young Sohn
Konstantin Othmer
b2venture
Edward Ludwig
Geberit Group
Ornament Health
Kirill Eves
Melih Odemis- ARAlejo Costa Ribalta
Red Bull Ventures
Marc Maurer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about LIOM on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LIOM’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.